Linatab M ER Tablet 2.5 mg + 1000 mg is an extended-release oral antidiabetic medication formulated for adults with type 2 diabetes mellitus (T2DM). It combines Linagliptin, a DPP-4 inhibitor, with Metformin Hydrochloride extended-release, providing a once-daily dosing option for convenient management of blood glucose.

The combination works through complementary mechanisms: Linagliptin enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner, targeting postprandial hyperglycemia, while Metformin ER reduces hepatic glucose production and improves insulin sensitivity, helping control fasting blood sugar. The extended-release formulation ensures steady plasma levels of Metformin, minimizing gastrointestinal side effects commonly associated with immediate-release formulations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Linagliptin: Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Metformin Hydrochloride ER: Biguanide antidiabetic agent

• Overall Class: Combination oral antidiabetic therapy

Pharmacology

Linagliptin:
Linagliptin inhibits DPP-4, the enzyme responsible for degrading incretin hormones like GLP-1 and GIP. By prolonging incretin activity, it enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release, reducing postprandial hyperglycemia without increasing hypoglycemia risk when used alone.

Metformin ER:
Metformin reduces hepatic glucose output and enhances peripheral glucose uptake, improving insulin sensitivity. The extended-release formulation allows for once-daily dosing, reduces peak plasma concentrations, and lowers the incidence of gastrointestinal discomfort compared to immediate-release Metformin.

Combination Effect:
Linatab M ER delivers comprehensive glycemic control, targeting both fasting and postprandial blood glucose levels, while simplifying therapy with once-daily administration, improving patient adherence.

Indications

Linatab M ER Tablet 2.5 mg + 1000 mg is indicated for:

• Adults with type 2 diabetes whose blood glucose is inadequately controlled with diet and exercise

• Patients requiring dual-action therapy combining insulin-independent and incretin-mediated glucose-lowering effects

• Adjunct therapy with other antidiabetic medications when monotherapy is insufficient

Dosage and Administration

• Recommended dose: 1 tablet orally once daily with the evening meal

• Adjust dose based on renal function, glycemic response, and tolerance

• Patients should maintain adequate hydration and continue lifestyle modifications including diet and exercise

Contraindications

• Type 1 diabetes or diabetic ketoacidosis

• Severe renal impairment, acute kidney injury, or metabolic acidosis

• Known hypersensitivity to Linagliptin, Metformin, or excipients

• Acute or chronic conditions predisposing to lactic acidosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Linatab M ER is generally well tolerated. Common side effects include:

• Gastrointestinal disturbances: nausea, diarrhea, abdominal discomfort

• Upper respiratory infections and nasopharyngitis

• Rare: hypoglycemia (when combined with insulin or sulfonylureas), lactic acidosis

Precautions and Warnings

• Monitor renal function regularly

• Temporarily discontinue Metformin ER in situations of acute illness, dehydration, or radiographic contrast exposure

• Educate patients about early signs of lactic acidosis: fatigue, muscle pain, rapid breathing, unusual sleepiness

Pregnancy and Lactation

• Not recommended during pregnancy or breastfeeding

• Use only if benefits outweigh risks after careful assessment by a healthcare provider

Storage Conditions

Store at room temperature below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children.